Browse > Article

Effect of Conditioning Regimen Intensity on Cytomegalovirus Infection and Related Risk Factors Analysis in Allogeneic Hematopoietic Stem Cell Transplantation  

Lee, Hye-Min (Department of Pharmacy, Samsung Medical Center)
Heo, Yoon-Jeong (Department of Pharmacy, Samsung Medical Center)
Im, Hyun-Jeong (Department of Pharmacy, Samsung Medical Center)
Chung, Seon-Young (Department of Pharmacy, Samsung Medical Center)
In, Yong-Won (Department of Pharmacy, Samsung Medical Center)
Jung, Chul-Won (Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Lee, Young-Mee (Department of Pharmacy, Samsung Medical Center)
Sohn, Kie-Ho (College of Pharmacy, Kyungsung University)
Publication Information
Korean Journal of Clinical Pharmacy / v.22, no.2, 2012 , pp. 123-130 More about this Journal
Keywords
Cytomegalovirus; Allogeneic hematopoietic stem cell transplantation; Reduced-intensity conditioning; Myeloablative conditioning;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Oh SJ, Lee KH, Lee JH, et al., The risk of cytomegalovirus infection in non-myeloablative peripheral stem cell transplantation compared with conventional bone marrow transplantation. J Korean Med Sci 2004; 19(2): 172-176.   DOI   ScienceOn
2 Choi SM, Lee DG, Choi JH, et al., Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation: A single-center experience in Korea. Int J Hematol 2005; 81(1): 69-74.   DOI   ScienceOn
3 Kim YK, Kim DW. Seroepidemiology of human cytomegalovirus in healthy adults measured by means of the anticomplement immuno fluorescence technique. Korean J Infect Dis 1992; 24: 87-92.
4 Giralt S. Reduced-intensity conditioning regimens for hematologic malignancies: What have we learned over the last 10 years?, Hematology Am Soc Hematol Educ Program 2005; 384-389.
5 Giralt S, Ballen K, Rizzo D, et al., Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15(3): 367-369.   DOI   ScienceOn
6 National Comprehensive Cancer Network. NCCN Guidelines for Supportive Care. Prevention and Treatment of Cancer-Related Infections v2. 2009. Available from: http:// www.nccn.org/professionals/physician_gls/f_guidelines. asp#infections
7 Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009; 113(23): 5711-5719.   DOI   ScienceOn
8 Schmidt-Hieber M, Schwarch S, Stroux A, et al., Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion. Int J Hematol 2010; 91(5): 877-885.   DOI   ScienceOn
9 Mohty M, Mohty AM, Blaise D, et al., Cytomegalovirusspecific immune recovery following allogeneic HLA identical sibling transplantation with reduced-intensity preparative regimen. Bone Marrow Transplant 2004; 33(8): 839-846.   DOI   ScienceOn
10 Mahallawy H, Salah F, Sharkawy N, et al., Level and onset of CMV-pp65 antigenemia as determinants of risk for CMV-related complications in stem cell transplant recipients. J Egypt Natl Canc Inst 2001; 13(4): 259-266.
11 Kline J, Pollyea DA, Stock W, et al., Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant 2006; 37(3): 307-310.   DOI   ScienceOn
12 Lamba R, Carrum G, Myers GD, et al., Cytomegalovirus (CMV) infections and CMV- specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with alemtuzumab. Bone Marrow Transplant 2005; 36(9): 797-802.   DOI   ScienceOn
13 Chakrabarti S, Mackinnon S, Chopra R, et al., High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002; 99(12): 4357-4363.   DOI   ScienceOn
14 Zaia J, Baden L, Boeckh MJ, et al., Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009; 44(8): 471-482.   DOI   ScienceOn
15 Engemann AM. Hematopoietic Stem Cell Transplantation (HSCT) / Blood and Marrow Transplantation (BMT). 2009 Oncology Pharmacy Preparatory Review Course, American College of Clinical Pharmacy / American Society of Health System Pharmacists, 358-438.
16 Cathleen M. Conditioning regimen in hematopoietic stem cell transplantation. In: Ezzone S, Schmit-pokorny K (eds). Blood and Marrow Stem Cell Transplantation: Principles, Practice, And Nursing Insights, 3rd edn. Jones & Bartlett : Sudbury, MA, 2005, 109-146.
17 Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34(8): 1094-1097.   DOI   ScienceOn
18 Boeckh M, Nichols WG, Papanicolaou G, et al., Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003; 9(9): 543-558.   DOI   ScienceOn
19 Ljungman P, Reusser P, Camara R de la, et al., Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant 2004; 33(11): 1075-1081.   DOI   ScienceOn
20 Cho EY, Park YS, Lee DH, et al., CMV antigenemia following pediatric hematopoietic stem cell transplantation : risk factors and outcomes. Korean J Pediatr 2006; 49(2): 173-180.   DOI
21 Satwani P, Baldinger L, Freedman J, et al., Incidence of viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant 2009; 15(12): 1587-1595.   DOI   ScienceOn
22 George B, Kerridge I, Gilroy N, et al., Fludarabine-based reduced intensity conditioning transplants have a higher incidence of cytomegalovirus reactivation compared with myeloablative transplants. Bone Marrow Transplant 2010; 45(5): 849-855.   DOI   ScienceOn
23 Schetelig J, Oswald O, Steuer N, et al., Cytomegalovirus infections in allogeneic stem cell recipients after reducedintensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia. Bone Marrow Transplant 2003; 32(7): 695-701.   DOI   ScienceOn
24 Martino R, Caballero MD, Canals C, et al., Reducedintensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001; 28(4): 341-347.   DOI   ScienceOn
25 Nakamura R. Cortez K, Solomon S, et al., High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 30(4): 235-242.   DOI   ScienceOn
26 Li CR, Greenberg PD, Gilbert MJ, et al., Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83(7): 1971-1979.